Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Where Do We Stand?

被引：5
|
作者：
Tsioulos, Georgios [1 ]
Kounatidis, Dimitris [2 ]
Vallianou, Natalia G. [3 ]
Poulaki, Aikaterini [4 ]
Kotsi, Evangelia [2 ]
Christodoulatos, Gerasimos Socrates [5 ]
Tsilingiris, Dimitrios [6 ]
Karampela, Irene [7 ]
Skourtis, Alexandros [8 ]
Dalamaga, Maria [9 ]
机构：
[1] Natl & Kapodistrian Univ Athens, Univ Gen Hosp Attikon, Med Sch, Dept Internal Med 4, Athens 12462, Greece
[2] Natl & Kapodistrian Univ Athens, Hippokrat Gen Hosp, Sch Med, Dept Internal Med 2, Athens 11527, Greece
[3] Sismanogleio Gen Hosp, Dept Internal Med 1, Athens 15126, Greece
[4] Natl & Kapodistrian Univ Athens, Sch Med, Dept Internal Med 2, Hematol Unit, Athens 11527, Greece
[5] Sismanogleio Gen Hosp, Dept Microbiol, Athens 15126, Greece
[6] Democritus Univ Thrace, Univ Hosp Alexandroupolis, Dept Internal Med 1, Alexandroupolis 68100, Greece
[7] Natl & Kapodistrian Univ Athens, Attikon Gen Univ Hosp, Med Sch, Dept Crit Care 2, Athens 12462, Greece
[8] Evangelismos Gen Hosp, Dept Internal Med, Athens 10676, Greece
[9] Natl & Kapodistrian Univ Athens, Med Sch, Dept Biol Chem, Athens 11527, Greece
来源：
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2024年 / 25卷 / 06期
关键词：
antisense oligonucleotides; atherosclerosis; cardiovascular disease; chronic inflammation; lepodisiran; lipoprotein(a); muvalaplin; small interfering RNAs; TRANSFER PROTEIN-INHIBITION; GENOME-WIDE ASSOCIATION; APOLIPOPROTEIN(A) ISOFORM SIZE; EXTENDED-RELEASE NIACIN; C-REACTIVE PROTEIN; OXIDIZED PHOSPHOLIPIDS; ELEVATED LIPOPROTEIN(A); REDUCES LIPOPROTEIN(A); STATIN TREATMENT; LOW-DENSITY;
D O I：
10.3390/ijms25063537
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Lipoprotein(a) [Lp(a)] consists of a low-density lipoprotein-like molecule and an apolipoprotein(a) [apo(a)] particle. Lp(a) has been suggested to be an independent risk factor of atherosclerotic cardiovascular disease (ASCVD). Lp(a) plasma levels are considered to be 70-90% genetically determined through the codominant expression of the LPA gene. Therefore, Lp(a) levels are almost stable during an individual's lifetime. This lifelong stability, together with the difficulties in measuring Lp(a) levels in a standardized manner, may account for the scarcity of available drugs targeting Lp(a). In this review, we synopsize the latest data regarding the structure, metabolism, and factors affecting circulating levels of Lp(a), as well as the laboratory determination measurement of Lp(a), its role in the pathogenesis of ASCVD and thrombosis, and the potential use of various therapeutic agents targeting Lp(a). In particular, we discuss novel agents, such as antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) that are currently being developed and target Lp(a). The promising role of muvalaplin, an oral inhibitor of Lp(a) formation, is then further analyzed.
引用
收藏
页数：35
相关论文
共 50 条
  • [1] High-Density Lipoprotein and Cardiovascular Disease-Where do We Stand?
    Iatan, Iulia
    Choi, Hong Y.
    Genest, Jacques
    ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2022, 51 (03) : 557 - 572
  • [2] Diabetes and atherosclerotic vascular disease. Where do we stand?
    Diaz Diaz, Jose Luis
    Dominguez Rodriguez, Tomas
    Argueso Armesto, Rosa Ma
    GALICIA CLINICA, 2014, 75 (03): : 123 - 130
  • [3] Obesity paradox in cardiovascular disease: where do we stand?
    Carbone, Salvatore
    Canada, Justin M.
    Billingsley, Hayley E.
    Siddiqui, Mohammad S.
    Elagizi, Andrew
    Lavie, Carl J.
    VASCULAR HEALTH AND RISK MANAGEMENT, 2019, 15 : 89 - 100
  • [4] Obstructive Sleep Apnea and Cardiovascular Disease: Where Do We Stand?
    Peker, Yuksel
    Akdeniz, Bahri
    Altay, Servet
    Balcan, Baran
    Basaran, Ozcan
    Baysal, Erkan
    Celik, Ahmet
    Dursunoglu, Dursun
    Dursunoglu, Nese
    Firat, Selma
    Gurkan, Canan Gunduz
    Ozturk, Onder
    Tasbakan, Mehmet Sezai
    Aytekin, Vedat
    Itil, Oya
    Cuhadaroglu, Caglar
    Atalar, Enver
    Yildirir, Aylin
    ANATOLIAN JOURNAL OF CARDIOLOGY, 2023, 27 (07): : 375 - 389
  • [5] Ibuprofen and cardiovascular safety: Where do we stand?
    Purcell, Henry
    JOURNAL OF THE ROYAL SOCIETY OF MEDICINE, 2007, 100 : 7 - 10
  • [6] COVID-19 pandemic and cardiovascular disease: where do we stand?
    Chatzis, Dimitrios G.
    Magounaki, Kalliopi T.
    Pantazopoulos, Ioannis N.
    Johnson, Elizabeth O.
    Tsioufis, Konstantinos P.
    MINERVA CARDIOANGIOLOGICA, 2020, 68 (04): : 347 - 358
  • [7] Cushing disease: Where do we stand, where are we heading?
    Fleseriu, Maria
    Petersenn, Stephan
    PITUITARY, 2015, 18 (02) : 179 - 180
  • [8] Cushing disease: Where do we stand, where are we heading?
    Maria Fleseriu
    Stephan Petersenn
    Pituitary, 2015, 18 : 179 - 180
  • [9] Low blood cholesterol and non-atherosclerotic disease mortality: Where do we stand?
    Smith, GD
    EUROPEAN HEART JOURNAL, 1997, 18 (01) : 6 - 9
  • [10] Cold Agglutinin Disease: Where Do We Stand, and Where Are We Going?
    Berentsen, Sigbjorn
    Malecka, Agnieszka
    Randen, Ulla
    Tjonnfjord, Geir E.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (01) : 35 - 44
12345